| Drug Name | Maker | Disease Category | Purpose | 2006 | 2009 | DrugBank |
|---|---|---|---|---|---|---|
| ABT-263 | Abbott | Cancer | Lymphoma, etc. | ? | PI | 0 |
| ABT-333 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
| ABT-143 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
| ABT-335 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
| ABT-510 (Thrombospondin Analogue) | Abbott | Cancer | Head, neck | ? | PII | 0 |
| ABT-751 | Abbott | Cancer | non-small cell lung | ? | PI-PII some studies terminated | 0 |
| ABT-894 | Abbott | Diabetes | Diabetic Neuropathies | ? | PII | 0 |
| ABT-450 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
| ABT-874 | Abbott | Autoimmune | Psoriasis | ? | PIII | |
| ABT-888 | Abbott | Cancer | Leukimia, Chronic Myeloproliferative Disorders | ? | PI, PII | 0 |
| ABT-869 | Abbott | Cancer | Solid tumor, advanced, metastatic | ? | PI PII | 0 |
| ABT-102 | Abbott | ? | ? | ? | PI | 0 |
| ABT-089 | Abbott | Neurological | ADHD | ? | PII some terminated | 0 |
| ABT-126 | Abbott | Neurological | Alzheimer's disease | ? | PI | 0 |
| ABT-072 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
| Cetrorelix Pamoate | AEterna Zentaris | Prostate | Benign prostatic hyperplasia | ? | PIII | 0 |
| CPI-300 | IntelGenx and Cary Pharmaceuticals | Neurological | antidepressant | ? | ? | 0 |
| Tigecycline (Tygacil) | Wyeth | Infectious, Antibiotic | MRSA | approved | approved | 00560DB |
| Mecasermin (Increlex) | Tercia | Hormone | Growth factor, synthetic IGF-1 | approved | approved | 01277DB |
| Dalbavancin (Zeven) | Pfizer | Infectious, Antibiotic | Gram+ (MRSA, MRSE) | Awaiting regulatory decision | PIII active | 0 |
| Denosumab (AMG 162) | Amgen | Osteoporosis | Treats osteoporosis | Late-stage trial | PIII active | 0 |
| Dimebolin, (Dimebon) | Medivation | Neurological | Alzheimer's disease | ? | PI PII | 0 |
| Gardasil | Merck | Infectious, virus | Vaccine prevents hpv/cervical cancer | Late-stage trial | approved | 0 |
| Ranibizumab (Lucentis) | Genentech, Novartis | Vision | Treats macular degeneration | Late-stage trial | approved | 01270DB |
| Belimumab (Benlysta or LymphoStat-B) | Human Genome Sciences, GlaxoSmithKline | Autoimmune | Treats lupus, rheumatoid arthritis | Mid-stage trial | PII active | 0 |
| Maraviroc | Pfizer | Infectious, virus | Treats HIV/AIDS | Late-stage trial | approved | 04835DB |
| Aflibercept (AVE005, VEGF-trap) | Regeneron | Cancer | Ovarian cancer | ? | PII PIII | 0 |
| Stamulumab (MYO-029) | Wyeth | Muscular dystrophy | Treats muscular dystrophy | Early-stage clinical trial | PII | 0 |
| Ciliary Neurotrophic Factor implant (NT-501) | Neurotech USA | Vision | RP, AMD, source of CNTF | ?? | PIII active | 0 |
| VEGF structural antagonist implant (NT-503) | Neurotech USA | Vision | wet AMD, source of VEGF antagonist | ?? | ?? | 0 |
| Disufenton sodium (NXY-059) | Renovis, AstraZeneca | Neurological | Stroke | Late-stage trial | PIII completed | 0 |
| Varenicline (Champix) | Pfizer | Neurological | Smoking addiction | Late-stage trial | approved | 01273DB |
| Tarenflurbil (Flurizan) | Myriad Genetics | Neurological | Alzheimer's disease | Late-stage trial | abandoned | 0 |
| Gaboxadol | Merck, Lundbeck | Neurological | Sleeplessness | Late-stage trial | abandoned | 0 |
| Indiplon | Neurocrine Biosciences, Pfizer | Neurological | Sleeplessness | Late-stage trial | abandoned? | 0 |
| Natalizumab(Tysabri, Antegren) | Biogen Idec, Elan | Neurological | Multiple sclerosis | FDA-approved but withdrawn | In use under observation | 00108DB |
| Ruboxistaurin (Arxxant) | Eli Lilly | Diabetes | Treat complications | Late-stage trial | PIII active | 0 |
| Tesaglitazar (Galida) | AstraZeneca | Diabetes | Lower blood sugar and cholesterol | Late-stage trial | abandoned | 0 |
| Vildagliptin (Galvus) | Novartis | Diabetes | Control blood sugar | Late-stage trial | abandoned 2008 | 0 |
| Sitagliptin (Januvia, MK-0431) | Merck | Diabetes | Control blood sugar | Late-stage trial | approved | 01261DB |
| Darapladib (480848 ) | GlaxoSmithKline | Cardiovascular | Prevent atherosclerosis and heart attack | Late-stage trial | Darapladib | 0 |
| Rimonabant (Acomplia) | Sanofi-Synthelabo | Cardiovascular | Combat obesity; reduce risk of heart disease | Awaiting regulatory decision | approved | 06155DB |
| AGI-1067 | AtheroGenics | Cardiovascular | Combat artery inflammation | Late-stage trial | abandoned | 0 |
| Alfimeprase | Nuvelo | Cardiovascular | Clot-buster | Late-stage trial | abandoned | 0 |
| Celacade | Vasogen | Cardiovascular | Treat heart failure | Late-stage trial | Celacade | 0 |
| Veliflapon (DG031) | DeCode Genetics | Cardiovascular | Combat artery inflammation | Mid-stage trial | PIII suspended ??deCODE in bankruptcy | 0 |
| ETC-216 | Pfizer, Esperion Therapeutics | Cardiovascular | Remove cholesterol from arteries | Mid-stage trial | ?? ETC-216 absent | 0 |
| ETC-1002 | Pfizer, Esperion Therapeutics | Cardiovascular | inhibit fatty acid synthesis, promote fatty acid degredation | ?? | Candidates | 0 |
| Lipitor-torcetrapib | Pfizer | Cardiovascular | Raise good cholesterol | Late-stage trial | Torcetrapib abandoned | 0 |
| CP-690,550 ( JAK-3 inhibitor) | Pfizer | Autoimmune | Rheumatoid Arthritis | ? | PIII | |
| LY518674 (PPAR alpha agonist) | Eli Lilly, Ligand Pharmaceuticals | Cardiovascular | Raise good cholesterol, lower triglycerides | Mid-stage trial | ?? | 0 |
| Aliskiren (Rasilez) | Novartis | Cardiovascular | Reduce high blood pressure | Late-stage trial | approved | 01258DB |
| Sitaxentan (Thelin) | Pfizer, Encysive Pharmaceuticals | Cardiovascular | Treat pulmonary hypertension | Awaiting regulatory decision | 0 approved outside US FDA letter | 0 |
| Acapodene | GTx | Cancer | Prostate cancer prevention | Late-stage trial | approved | 00539DB |
| Ridaforolimus (AP23573) | Ariad Pharmaceuticals | Cancer | Sarcoma | Mid-stage trial | recruiting PIII | 0 |
| Abatacept (Orencia) | Bristol-Myers Squibb | Autoimmune | Rheumatoid arthritis | ? | PIII | 0 |
| Dasatinib | Bristol-Myers Squibb | Cancer | Leukemia | Awaiting regulatory decision | approved | 01254DB |
| Ipilimumab | Medarex, Bristol-Myers Squibb | Cancer | Melanoma | Late-stage trial | active PIII | 0 |
| Panitumumab | Amgen | Cancer | Colon cancer, other tumors | Awaiting regulatory decision | approved | 01269DB |
| Vatalanib (PTK-787) | Novartis, Schering | Cancer | Colon cancer | Late-stage trial | active PIII | 0 |
| Provenge | Dendreon | Cancer | Prostate cancer | Late-stage trial | active PIII | 0 |
| Telcyta (TLK286) | Telik | Cancer | Ovarian cancer | Late-stage trial | active PIII | 0 |
| Ticilimumab | Pfizer | Cancer | Melanoma | Mid-stage trial | active PIII | 0 |
| Lapatinib | GlaxoSmithKline | Cancer | Breast cancer, bladder cancer | Late-stage trial | approved | 01259DB |
| Bavituximab | Perigrine Pharmaceuticals | Cancer | Solid tumer | ? | PI PII | 0 |
| Cotara 131I-chTNT-1/B MAb | Perigrine Pharmaceuticals | Cancer | Glioblastoma | ? | PI PII | 0 |
| Elesclomol | Synta | Cancer | Melanoma, metastatic | ? | PII some suspended | 0 |
| Fostamatinib disodium (R935788) | Rigel | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
| Palladia | Pfizer | Cancer | For Dogs | ? | 0 | |
| Arzerra | Genmab, GlaxoSmithKline | Cancer | lymphocytic leukemia | Collab. initiated | PII | 0 |
| Apremilast | Celgene | autoimmune | psoriatic arthritis | ? | PII | 0 |
| Aldesleukin (Proleukin) | Novartis | Cancer | Metastatic melanoma, metastatic kidney | ? | PI PII | 0 |
| Darusentan | Gilead Sciences | Cardiovascular | Hypertension | ? | PIII | 0 |
| Stimuvax (BLP25) | Oncothyreon, Merk Serono | Cancer | Carcinoma, Non-Small-Cell Lung; breast cancer | ? | PII PII | 0 |
| Ocrelizumab | Genentech | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
| Cixutumumab | ImClone | Cancer | Solid tumors | ? | PII | 0 |
| NVA237 | Novartis, Vectura | Pulmonary | chronic obstructive pulmonary disease | ? | PII PIII | 0 |
| SEP-225289 | Sepracor | Neurological | Depressive disorder, major | ? | PII | 0 |
| Lu AA24530 | Lundbeck | Neurological | Depressive disorder, major | ? | PII | 0 |
| PRO-040201 | Tekmira Pharmaceuticals Corporation | Cardiovascular | Hypercholesterolemia | ? | PI | 0 |
| TB-402 | ThromboGenics, BioInvent | Cardiovascular | Blood thinner | ? | PII | 0 |
| Saxagliptin (Onglyza, BMS-477118) | Bristol-Meyers Squibb | Metabolic | Diabetes, type 2 | ? | PIII | 0 |
This is the start of my user page. I want to contribute to articles pertaining to electricity generation and the politics and economics thereof. It would be great to see more work in this area from various wikipedia contributors.
| BPA transmission line uprgrades per 2005[1] | Status | Project Start | Project Completion | Miles | kV | Structure | Capacity increase, MW | Cost per mile | Cost per added watt capacity | Sub-station | Total cost |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WA | |||||||||||
| Franklin to Walla Walla | Pending | 2005 | 2005 | 18.5 | 115 | ? | ? | $302,703 | ? | ? | $5,600,000 |
| Grand Coulee to Bell | Completed | ? | 2004 | 84 | 500 | steel latice | 1500 | $1,892,857 | $0.11 | ? | $159,000,000 |
| Kangley to Echo Lake | Completed | 2000 | 2003 | 9 | 500 | ? | ? | $9,333,333 | ? | yes | $84,000,000 |
| Raymond to Cosmopolis Rebuild | Completed | ? | 2004 | 18 | 115 | s.steel pole | ? | $622,222 | ? | ? | $11,200,000 |
| Schultz to Wautona | Construction | ? | 2005? | 63 | 500 | ? | 600 | $2,761,905 | $0.29 | yes | $174,000,000 |
| Hopkins Ridge Wind Intercnctn | Pending | 2005 | ? | 115 | ? | ? | 150 | ? | ? | ? | ? |
| OR | |||||||||||
| Albany to Eugene Rebuild | Completed | 2004 | 18 | 115 | ? | ? | ? | $411,111 | ? | ? | $7,400,000 |
| Fort Yamhill Relocation | Pending | 2005 | ? | 115 | ? | ? | ? | ? | ? | ? | ? |
| Combine Hills Wind Intercnctn | Pending | 2005 | ? | 5.8 | ? | wood | 63 | ? | ? | ? | ? |
| Klondike III Wind Intercntctn | Pending | 2005 | 2006 | 10 | 230 | ? | 300 | ? | ? | ? | ? |
| MT | |||||||||||
| Libby to Troy Rebuild | Pending | 2005 | 17 | 115 | ? | ? | ? | ? | ? | ? | ? |
| ID | |||||||||||
| Anderson Ranch to Mountain Home Rebuild | 2004 | 18 | 115 | steel pole | ? | ? | ? | $194,444 | ? | ? | $3,500,000 |
| Swan Valley to Goshen Rebuild | 2004 | 2006 | 25 | 161 | ? | wood | ? | $128,000 | ? | ? | $3,200,000 |
| HEAD1 | HEAD2 | HEAD3 | HEAD4 | HEAD5 |
|---|---|---|---|---|
| R1C1 | R1C2 | R1C3 | R1C4 | R1C5 |
| R2C1 | R2C2 | R2C3 | R2C4 | R2C5 |